Antiproteinuric Efficacy of Losartan Potassium in Patients With Non-Diabetic Proteinuric Renal Diseases
Information source: Merck
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Renal Disorder
Intervention: MK0954, losartan potassium/Duration of Treatment: 20 weeks (Drug); Comparator: amlodipine / Duration of Treatment: 20 weeks (Drug)
Phase: Phase 4
Status: Active, not recruiting
Sponsored by: Merck Official(s) and/or principal investigator(s):
Medical Monitor, Study Director, Affiliation: Merck
Summary
Antiproteinuric Efficacy of Losartan Potassium in Patients with Non-Diabetic Proteinuric
Renal Diseases.
Clinical Details
Official title: Antiproteinuric Efficacy of Losartan Potassium in Patients With Non-Diabetic Proteinuric Renal Diseases
Study design: Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Efficacy Study
Primary outcome: 24h proteinuria
Secondary outcome: Changes in the plasma and urinary levels of TGF-beta
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Males or females at least 18 years of age with non-diabetic proteinuric renal
diseases
Locations and Contacts
Merck Sharp & Dohme De Espana, S.A.E., Madrid 28027, Spain
Additional Information
Starting date: January 2000
Last updated: October 25, 2005
|
